



OPEN

FEN1 -69G>A and 4150G>T polymorphisms and cancer risk in Chinese population

SUBJECT AREAS:
PREDICTIVE MARKERS
DIAGNOSTIC MARKERSXue-ren Gao^{1*}, Shu-long Zhang^{2*}, Yong-feng Yang³ & Guo-rong Han⁴Received
16 June 2014Accepted
4 August 2014Published
26 August 2014Correspondence and
requests for materials
should be addressed to
G.H. (hangr210009@
163.com)* These authors
contributed equally to
this work.

¹Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, China, ²Department of General Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China, ³Department of Infectious Diseases, The Second Affiliated Hospital of the Southeast University, Nanjing, China, ⁴Department of Gynecology and Obstetrics, The Second Affiliated Hospital of the Southeast University, Nanjing, China.

Previous studies have investigated the associations between *FEN1* -69G>A (rs174538) and 4150G>T (rs4246215) polymorphisms and cancer risk in Chinese population. However, the results were controversial. We therefore carried out a meta-analysis to derive a more precise estimation of the associations. PubMed Database was systematically searched to identify potentially eligible literatures. Crude odds ratios (ORs) and their 95% confidence intervals (CIs) were used to assess the strength of associations between *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk in Chinese population. A total of 4 articles, including 5,108 cases and 6,382 controls, were used to evaluate the effect of the two polymorphisms on cancer risk. The pooled ORs indicated that *FEN1* -69G>A and 4150G>T polymorphisms were significantly associated with cancer risk in Chinese population. In stratified analyses by cancer type, significant associations were also observed in digestive system cancer. In addition, haplotypes consisting of -69G>A and 4150G>T polymorphisms were closely associated with cancer risk. Interestingly, significant correlation between *FEN1* -69G>A polymorphism and mRNA expression was observed. In conclusion, this meta-analysis suggests that *FEN1* -69G>A and 4150G>T polymorphisms may be associated with cancer susceptibility in Chinese population. However, further investigation on large population and different ethnicities are warranted.

Cancer is one of serious diseases threatening public health. About 12.7 million cases were diagnosed and 7.6 million patients died from cancer in 2008¹. The pathogenesis of cancer remains unknown, but evidence from epidemiological and genetic studies has indicated significant association between inherited and environmental factors and cancer development^{2–4}.

DNA repair systems play critical roles in protecting against mutations and are essential for maintaining the integrity of the genome. Reduced DNA repair capacity (DRC) is reportedly related to an increased risk of cancer⁵, and single nucleotide polymorphisms (SNPs) located in DNA repair genes may affect gene function and thereby debilitate DRC⁶.

Flap endonuclease 1 (*FEN1*) is an evolutionarily conserved component of DNA replication in humans. Based on in vitro results, it processes Okazaki fragments during replication and is involved in base excision repair. *FEN1* removes the last primer ribonucleotide on the lagging strand and it cleaves a 5-prime flap that may result from strand displacement during replication or during base excision repair^{7–9}. In addition, the conserved *FEN1* carboxyl terminus binds proliferating cell nuclear antigen and positions *FEN1* to act primarily as an exonuclease in DNA replication, in contrast to its endonuclease activity in DNA repair. Therefore, *FEN1* play a vital role in maintaining genomic stability and protecting against carcinogenesis.

FEN1 gene is located on the chromosome 11q12.2 region and has some common genetic polymorphisms identified. Among them, -69G>A (rs174538) and 4150G>T (rs4246215) polymorphisms have been gaining great attention. Previous studies have suggested that the two polymorphisms in *FEN1* may function as biomarkers for cancer risk in Chinese population, including breast cancer, glioma, hepatocellular carcinoma, esophageal cancer, gastric cancer, colorectal cancer, etc^{10–13}. However, these studies had relatively small sample sizes, and may lack enough power to assess the associations between *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk in Chinese population. Hence, we performed this meta-analysis from all eligible case-control studies to provide a more precise estimation of the associations.




Figure 1 | The flow chart of literature search and study selection.

Results

Characteristics of Studies. Figure 1 and Table 1 show the study selection process and main characteristics of included studies, respectively. A total of 9 articles were retrieved based on the search criteria^{10–18}. Among them, 3 articles were excluded through screening title and abstract^{14,17,18}. Then, 2 articles without *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk were excluded^{15,16}. Thus, a total of 4 articles with 5,108 cancer cases and 6,382 controls were included in the meta-analysis^{10–13}. For the -69G>A polymorphism, 7 studies were available, including a total of 5,108 cases and 6,381 controls. For the 4150G>T polymorphism, 7 studies involved a total of 5,071 cases and 6,381 controls. Among them, 4 studies focused on digestive system cancer including hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer, 3 involved with other system cancer, such as breast cancer, glioma and lung cancer. Frequency distribution of the *FEN1* -69G>A and 4150G>T haplotypes is shown in Supplement Table S1. A total of 4 studies with 10,669 cases and 12,761 controls were combined to test the difference in the frequencies of haplotypes. In addition, there are 2 articles involved *FEN1* -69G>A polymorphism and *FEN1* mRNA expression in normal tissues (Supplement Table S2). In the two articles including five studies, the same assay method (SYBR-Green real-time quantity PCR) and internal reference (β -actin) were used to examine *FEN1* mRNA levels. Thus, they were pooled to assess the genotype-mRNA expression correlation.

Quantitative data synthesis. Results of *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk are presented in Table 2 and Figure 2. For the -69G>A polymorphism, significant association was observed in all cancer type combined study, including breast cancer, glioma, hepatocellular carcinoma, esophageal cancer, gastric cancer, colorectal cancer and lung cancer (A vs. G: OR = 0.73, 95%CI: 0.69–0.77, P_H = 0.20; AA vs. GG: OR = 0.54, 95%CI: 0.48–0.61, P_H = 0.31; AG vs. GG: OR = 0.76, 95%CI: 0.70–0.82, P_H = 0.39; (AA+AG) vs. GG: OR = 0.70, 95%CI: 0.65–0.75, P_H = 0.26; AA vs. (AG+GG): OR = 0.62, 95%CI: 0.56–0.69, P_H = 0.51). Subgroup analysis by cancer type showed that statistically significant associations were also found among digestive system cancer (A vs. G: OR = 0.72, 95%CI: 0.66–0.79, P_H = 0.99; AA vs. GG: OR = 0.50, 95%CI: 0.41–0.61, P_H = 0.96; AG vs. GG: OR = 0.80, 95%CI: 0.70–0.91, P_H = 0.99; (AA+AG) vs. GG: OR = 0.71, 95%CI: 0.63–0.81, P_H = 1.00; AA vs. (AG+GG): OR = 0.56, 95%CI: 0.47–0.68, P_H = 0.94).

For the 4150G>T polymorphism, significant associations with cancer risk were observed in all cancer type combined study (T vs.

Table 1 | Main Characteristics of Included Studies in the Meta-Analysis

First author	Year	Country	Cancer type	Genotyping	Source of control	-69G>A rs174538		4150G>T rs4246215	
						Case AA/GA/GG	Control AA/GA/GG	Case TT/GT/GG	Control TT/GT/GG
Lv, Z.	2014	China	Breast cancer	PCR-RFLP	Community cancer-screening program for early detection of cancer	116/437/547	246/639/515	134/449/517	246/651/503
Chen, Y. D. Liu, L.	2013 2012	China China	Glioma Hepatocellular carcinoma	PCR-RFLP PCR-RFLP	Hospital Community cancer-screening program for early detection of cancer	35/122/160 68/290/290	130/356/316 134/334/270	34/120/160 73/295/280	130/363/309 129/335/274
Yang, M.	2009	China	Esophageal cancer Gastric cancer Colorectal cancer Lung cancer	PCR-RFLP, TaqMan	Community nutritional survey, Community screening program for early detection of cancer and chronic noninfectious disease	62/249/244 41/182/189 28/104/104 253/796/791	128/331/263 76/209/169 54/144/109 354/880/724	58/255/225 42/177/183 27/102/100 271/815/754	125/336/262 76/212/166 52/145/109 358/883/717

Table 2 | Results of meta-analysis for *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk

Polymorphism	Allele model		Homozygous model		Heterozygous model		Dominant model		Recessive model		
	A vs. G		AA vs. GG		AG vs. GG		(AA+AG) vs. GG		AA vs. (AG+GG)		
	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H	
-69G>A	Total	0.73 (0.69–0.77)	0.20	0.54 (0.48–0.61)	0.31	0.76 (0.70–0.82)	0.39	0.70 (0.65–0.75)	0.26	0.62 (0.56–0.69)	0.51
	DSC	0.72 (0.66–0.79)	0.99	0.50 (0.41–0.61)	0.96	0.80 (0.70–0.91)	0.99	0.71 (0.63–0.81)	1.00	0.56 (0.47–0.68)	0.94
	Other	0.72 (0.61–0.84)	0.02	0.56 (0.49–0.65)	0.05	0.74 (0.67–0.82)	0.07	0.67 (0.55–0.81)	0.03	0.65 (0.57–0.75)	0.21
4150G>T	Total	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H	OR (95%CI)	P_H
	DSC	0.77 (0.73–0.81)	0.19	0.59 (0.53–0.67)	0.37	0.79 (0.73–0.86)	0.16	0.74 (0.68–0.79)	0.13	0.67 (0.60–0.75)	0.61
	Other	0.76 (0.69–0.83)	0.95	0.54 (0.44–0.66)	0.98	0.83 (0.73–0.95)	0.82	0.75 (0.66–0.86)	0.87	0.60 (0.50–0.72)	0.98
		0.75 (0.64–0.87)	0.02	0.62 (0.54–0.72)	0.09	0.74 (0.60–0.91)	0.02	0.69 (0.56–0.86)	0.01	0.71 (0.63–0.81)	0.40

Allele model (A vs. G); (AA*2+GA) vs. (GG*2+GA); DSC: Digestive system cancer; P_H : P value for the heterogeneity test.

G: OR = 0.77, 95%CI: 0.73–0.81, P_H = 0.19; TT vs. GG: OR = 0.59, 95%CI: 0.53–0.67, P_H = 0.37; TG vs. GG: OR = 0.79, 95%CI: 0.73–0.86, P_H = 0.16; (TT+TG) vs. GG: OR = 0.74, 95%CI: 0.68–0.79, P_H = 0.13; TT vs. (TG+GG): OR = 0.67, 95%CI: 0.60–0.75, P_H = 0.61). In the subgroup analysis by cancer type, statistically significant associations were found in digestive system cancer (T vs. G: OR = 0.76, 95%CI: 0.69–0.83, P_H = 0.95; TT vs. GG: OR = 0.54, 95%CI: 0.44–0.66, P_H = 0.98; TG vs. GG: OR = 0.83, 95%CI: 0.73–0.95, P_H = 0.82; (TT+TG) vs. GG: OR = 0.75, 95%CI: 0.66–0.86, P_H = 0.87; TT vs. (TG+GG): OR = 0.60, 95%CI: 0.50–0.72, P_H = 0.98).

In haplotype analysis (Table 3), the *FEN1* haplotype (G₆₉G₄₁₅₀) comprising the major alleles was taken as reference. The pooled results indicated that G₆₉T₄₁₅₀, A₆₉G₄₁₅₀ and A₆₉T₄₁₅₀ haplotypes were significantly associated with cancer risk (G₆₉T₄₁₅₀ vs. G₆₉G₄₁₅₀: OR = 0.68, 95%CI: 0.55–0.83, P_H = 0.00; A₆₉G₄₁₅₀ vs. G₆₉G₄₁₅₀: OR = 0.41, 95%CI: 0.32–0.51, P_H = 0.00; A₆₉T₄₁₅₀ vs. G₆₉G₄₁₅₀: OR = 0.76, 95%CI: 0.70–0.82, P_H = 0.00).

For *FEN1* -69G>A polymorphism and *FEN1* mRNA expression (Figure 3), the pooled analysis revealed that *FEN1* mRNA levels were different between subjects with the -69AA genotype and those with the -69GG and GA genotypes in all included normal tissues ($P < 0.001$).

Sensitivity analysis. The sensitivity analysis indicated that no single study influenced the pooled OR value, either for *FEN1* -69G>A polymorphism or for *FEN1* 4150G>T polymorphism, suggesting that the results of this meta-analysis are stable (data not shown).

Publication bias. Publication bias of the included articles was assessed using Begg's funnel plot. As shown in Figure 4, the shape of the funnel plot was symmetrical and did not show an obvious publication bias for *FEN1* -69G>A or 4150G>T polymorphism.

Discussion

To the best of our knowledge, this is the first meta-analysis providing comprehensive insights into the effects of *FEN1* -69G>A and 4150G>T polymorphisms on the risk of cancer. For the -69G>A polymorphism in the *FEN1* promoter region, the overall results suggested that the subjects with A allele caused an decreased susceptibility to cancer in Chinese populations. For the 4150G>T polymorphism in the *FEN1* 3'-untranslated region, results showed that subjects with T allele were associated with the decreased risk of cancer in Chinese populations. However, the previous results showed no associations between the two polymorphisms and the risk of colorectal cancer¹¹. Considering that the previous single-institution study for colorectal cancer has a small sample size and may not justify the significance of current work, further studies are needed to clarify the effect of the two polymorphisms on the risk of colorectal cancer. In addition, the current results were consistent with the biological function studies. Transient transfection and luciferase assays showed that *FEN1*, a tumor suppressor gene, -69A or 4150T variant has heightened expression in vitro¹³. According to cancer type, significantly decreased risks were also observed in digestive system cancer. In addition, similar results were observed in *FEN1* haplotype analysis. Namely, G₆₉T₄₁₅₀, A₆₉G₄₁₅₀ and A₆₉T₄₁₅₀ haplotypes were significantly associated with the decreased risk of cancer in Chinese populations. Interestingly, -69G>A polymorphism is significantly associated with not only cancer risk but also *FEN1* mRNA levels in normal tissues. Subjects with the -69AA genotype had significantly higher *FEN1* mRNA levels than those with the -69GG and GA genotypes.

Some limitations should be considered when interpreting our results. Firstly, our results were based on unadjusted estimates, since more accurate outcomes should be adjusted by other confounders including gender, age, body mass index, lifestyle, etc. Secondly, all eligible studies included in this analysis were insufficient, especially




Figure 2 | Forest plots for *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk in the heterozygous model. (A: *FEN1* -69G>A polymorphism; B: *FEN1* 4150G>T polymorphism; Liu, L. 1-4 indicate Liu, L.'s study of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer, respectively).

in subgroup analysis. Thus, potential publication bias was very likely to exist, in spite of no significant publication bias in our meta-analysis. Thirdly, language of all included studies was limited to English, which may result in potential language bias. Last but not least, the interaction of gene-environment had not been evaluated owing to the absence of original data. However, some advantages should be highlighted in this meta-analysis. The current research could shed

lights on the relationship of *FEN1* -69G>A and 4150G>T polymorphisms and the decreased susceptibility to cancer in Chinese population, comprehensively and systematically. Additionally, the present research, which had a larger sample size, could enhance the power and persuasion of our conclusion when compared with previous study.

In summary, our meta-analysis suggests that *FEN1* -69G>A and 4150G>T polymorphisms and their haplotypes are associated with cancer risk, and *FEN1* -69G>A polymorphism are associated with *FEN1* mRNA expression in normal tissues. However, larger sample sizes of different ethnic populations are required to confirm our findings.

Methods

Search strategy and inclusion criteria. We systematically searched literature from PubMed for all relevant studies using the following terms: “flap endonuclease or FNE1” “polymorphism” and “cancer” (up to June 14, 2014). In addition, the references of all retrieved articles were also manually searched for additionally relevant publications. Criteria for eligible studies were as follows: (a) case-control

Table 3 | Results of meta-analysis for *FEN1* haplotypes and cancer risk

Haplotypes	vs. G ₆₉ G ₄₁₅₀	
	OR (95%CI)	P _H
G ₆₉ T ₄₁₅₀	0.68 (0.55–0.83)	0.00
A ₆₉ G ₄₁₅₀	0.41 (0.32–0.51)	0.00
A ₆₉ T ₄₁₅₀	0.76 (0.70–0.82)	0.00




Figure 3 | The pooled results of *FEN1* -69G>A polymorphism and *FEN1* mRNA expression in recessive model. (-69AA: *FEN1* mRNA levels in subjects with the -69AA genotype; -69AG+GG: *FEN1* mRNA levels in subjects with the -69AG and -69GG genotype).




Figure 4 | Funnel plots of *FEN1* -69G>A and 4150G>T polymorphisms in the heterozygous model. (A: *FEN1* -69G>A polymorphism; B: *FEN1* 4150G>T polymorphism).

studies, (b) evaluating the association between *FEN1* -69G>A and/or 4150G>T polymorphisms and cancer risk in Chinese population, (c) and sufficient information for calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs).

Data extraction. The re-sampling method was performed as described previously¹⁹. Two authors independently extracted data from eligible studies^{10–13}. The following information was collected from each study: first author's name, year of publication, country of origin, cancer type, source of control, genotyping methods, the frequency distribution of -69G>A and 4150G>T genotypes/alleles/haplotypes. In addition, data of correlations between *FEN1* -69G>A polymorphism and *FEN1* mRNA expression in normal tissues were also extracted from eligible studies^{11,12}. Any disagreements were resolved by discussion with a third investigator.

Statistical Methods. All statistical analyses were carried out with the Stata software version 12.0 (Stata Corporation, College Station, TX) and RevMan 5.0 software. Heterogeneity among studies was tested using the Chi square-based Q-test, and *P* value for the heterogeneity test (P_H) < 0.05 was regarded as statistically significant. Based on the heterogeneity test, the pooled OR was calculated using the fixed ($P_H \geq 0.05$) or random ($P_H < 0.05$) effects model. The strength of the associations between *FEN1* -69G>A and 4150G>T polymorphisms and their haplotypes and cancer risk was measured by ORs with 95% CIs. The pooled ORs were also estimated for -69G>A by homozygous (AA vs. GG), heterozygous (AG vs. GG), dominant [(AA+AG) vs. GG] and recessive models [AA vs. (AG+GG)] as well as allele model (A vs. G) and so was 4150G>T by homozygous (TT vs. GG), heterozygous (TG vs. GG), dominant [(TT+TG) vs. GG] and recessive models [TT vs. (TG+GG)] as well as allele model (T vs. G). For *FEN1* -69G>A and 4150G>T haplotypes, the pooled ORs were estimated by comparison with G₆₉G₄₁₅₀ haplotype (G₆₉T₄₁₅₀ vs. G₆₉G₄₁₅₀, A₆₉G₄₁₅₀ vs. G₆₉G₄₁₅₀, A₆₉T₄₁₅₀ vs. G₆₉G₄₁₅₀). In addition, ORs and 95% CIs were used to assess the associations between *FEN1* -69G>A polymorphism and *FEN1* mRNA expression in normal tissues. Subsequently, in order to ensure that no individual study was entirely responsible for the combined results, sensitivity analysis was performed by omitting each study in turn to assess the quality and consistency of the results. Begg's funnel plot was used to evaluate possible publication bias of literatures. All the *P* values < 0.05 were considered significant.

- Jemal, A. *et al.* Global cancer statistics. *CA Cancer J Clin* **61**, 69–90 (2011).
- Gao, X. *et al.* Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. *PLoS one* **8**, e55169 (2013).

- Xu, L., Huang, S., Chen, W., Song, Z. & Cai, S. NFKB1 -94 insertion/deletion polymorphism and cancer risk: a meta-analysis. *Tumour Biol* **35**, 5181–5187 (2014).
- Ying, H., Wang, J. & Gao, X. CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects. *Tumour Biol* **35**, 5895–5904 (2014).
- Shen, H. *et al.* Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. *Int J Cancer* **107**, 84–88 (2003).
- Xi, T., Jones, I. M. & Mohrenweiser, H. W. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. *Genomics* **83**, 970–979 (2004).
- Harrington, J. J. & Lieber, M. R. The characterization of a mammalian DNA structure-specific endonuclease. *EMBO J* **13**, 1235–1246 (1994).
- Lieber, M. R. The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. *Bioessays* **19**, 233–240 (1997).
- Shen, B. *et al.* Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. *Bioessays* **27**, 717–729 (2005).
- Chen, Y. D. *et al.* Functional FEN1 genetic variants and haplotypes are associated with glioma risk. *J Neurooncol* **111**, 145–151 (2013).
- Liu, L. *et al.* Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. *Carcinogenesis* **33**, 119–123 (2012).
- Ly, Z. *et al.* Association of functional FEN1 genetic variants and haplotypes and breast cancer risk. *Gene* **538**, 42–45 (2014).
- Yang, M. *et al.* Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. *Hum Mutat* **30**, 1320–1328 (2009).
- Chen, Y. *et al.* A NELL1 single nucleotide polymorphism (rs4462560) predicts the risk of radiation-induced toxicities in esophageal cancer patients treated with definitive radiotherapy. *Cancer* **119**, 4205–4211 (2013).
- Corral, R. *et al.* Genetic variation in the base excision repair pathway, environmental risk factors, and colorectal adenoma risk. *PLoS one* **8**, e71211 (2013).
- Li, W. Q. *et al.* Genetic variants in DNA repair pathway genes and risk of esophageal squamous cell carcinoma and gastric adenocarcinoma in a Chinese population. *Carcinogenesis* **34**, 1536–1542 (2013).
- Ma, X., Jin, Q., Forst, A., Hemminki, K. & Kumar, R. Single nucleotide polymorphism analyses of the human proliferating cell nuclear antigen (pCNA) and flap endonuclease (*FEN1*) genes. *Int J Cancer* **88**, 938–942 (2000).
- Mitra, A. K. *et al.* Association of polymorphisms in base excision repair genes with the risk of breast cancer: a case-control study in North Indian women. *Oncol Res* **17**, 127–135 (2008).



19. Li, J. *et al.* Identification of high-quality cancer prognostic markers and metastasis network modules. *Nat Commun* 1:34 (2010).

Author contributions

Conceived and designed the experiments: H.G., G.X. Performed the experiments: H.G., G.X., Z.S. Analyzed the data: G.X., Z.S. Contributed reagents/material/analysis tools: H.G., G.X., Z.S. Wrote the main manuscript text: H.G., G.X. Reference collection and data management: H.G., G.X., Z.S., Y.Y. Statistical analyses and paper writing: H.G., G.X., Z.S. Study design: H.G., G.X., Z.S., Y.Y. Prepared figures 1–4: Y.Y. All authors reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Gao, X.-R., Zhang, S.-L., Yang, Y.-F. & Han, G.-R. *FEN1* -69G>A and 4150G>T polymorphisms and cancer risk in Chinese population. *Sci. Rep.* 4, 6183; DOI:10.1038/srep06183 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>